SC
BPMC

Stephens Consulting’s Blueprint Medicines BPMC Stock Holding History

Stephens Consulting’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20
Closed -$1.77K – 1315
2025
Q1 		$1.77K Buy
+20
New +$1.95K ﹤0.01% 469
2024
Q3 		– Sell
-33
Closed -$3.56K – 540
2024
Q2 		$3.56K Buy
+33
New +$3.3K ﹤0.01% 445

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Stephens Consulting's BPMC Position: Q2 2025 in Review

Stephens Consulting sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 20 shares — an estimated $1.77K sold.

Stephens Consulting first reported a position in BPMC in Q2 2024 and held it in 2 quarters. The position peaked at $3.56K in Q2 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Stephens Consulting reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 20 Blueprint Medicines shares in Q2 2025, an estimated $1.77K.
  • Stephens Consulting first reported a position in Blueprint Medicines in Q2 2024 and held it in 2 quarters.
  • Stephens Consulting's Blueprint Medicines position peaked at $3.56K in Q2 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.